News

Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.

AstraZeneca and Ionis Pharmaceuticals shares are down roughly 8% and 20%, respectively, after the drugmakers said their heart therapy Wainua failed in a late-stage trial. The companies pointed to a smaller group of patients in the trial to show some potential for the drug: Patients who weren’t already taking either Pfizer or BridgeBio’s drug for this condition saw a relative risk reduction in major heart problems or deaths.

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a

In a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.

All three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite